

NIVS Communication 8th February 2023

From: NIVS NIVS <NIVS@england.nhs.uk>

Sent: 08 February 2023 15:34

Subject: NIVS release - please read

Dear NIVS Users,

Please distribute this to all NIVS users in your organisation

Changes to 5–11-year booster warnings – 8th February 2023

Please be advised that the below warning now appears in NIVS for a child who have been deemed not at risk but is eligible for their booster. This does not stop you from vaccinating. This warning appears on Pre-Screening and will appear in the Add Vaccination section too as in the second screenshot.

The first screenshot shows a form with the following fields:

- Eligibility Type: Individual is eligible due to their age?
- Planned Vaccine Type: Comirnaty Children 5-11 years 10micrograms/0.2ml dose (Pfizer)
- Dose: Booster Dose

A yellow warning box is displayed below the Dose field, containing the text: "A booster dose should only be administered to a patient age 5-11 or in School Year 7 if they are at risk. Please review [The Green Book](#) for further guidance."

The second screenshot is a zoomed-in view of the Dose dropdown menu, which is set to "Booster Dose". Below the dropdown, the same yellow warning box is visible, with the text: "A booster dose should only be administered to a patient age 5-11 or in School Year 7 if they are at risk."


Please be advised that the below warning now appears in NIVS on pre-screening and Add Vaccination section for a child who have been deemed at risk and is having an adult vaccine. The warning indicates that this vaccine has been given outside of JCVI guidelines. This does not stop you from vaccinating. Please see below screenshots for clarification.

* indicates a required field


Eligibility Type
Individual is clinically at risk?

Planned Vaccine Type
Comirnaty 30micrograms/0.3ml dose (Pfizer)

Dose
Booster Dose


 You have selected the Comirnaty 30micrograms/0.3ml dose (Pfizer) for a person under the age of 12 or in School Year 7. This is currently not advised by JCVI and is outside MHRA authorisations. This can only be administered on the instruction of a prescribing clinician e.g. Doctor. Please discuss the appropriateness of vaccination with the prescriber BEFORE vaccination. If they give authority to vaccinate it should be recorded as authorised under Patient Specific Direction (PSD). Please record in the Comment box below why this vaccine has been chosen.

Vaccine Type
Comirnaty 30micrograms/0.3ml dose (Pfizer)

 You have selected the Comirnaty 30micrograms/0.3ml dose (Pfizer) for a person under the age of 12 or in School Year 7. This is currently not advised by JCVI and is outside MHRA authorisations. This can only be administered on the instruction of a prescribing clinician e.g. Doctor. Please discuss the appropriateness of vaccination with the prescriber BEFORE vaccination. If they give authority to vaccinate it should be recorded as authorised under Patient Specific Direction (PSD).

Batch Validation- 8th February 2023

If you enter a batch number that doesn't confirm to the specification then you will receive a warning (screenshot below) but you can still proceed with the vaccination



- Please be advised all user guides and training videos are available here: [COVID-19 National immunisation and vaccination programme - NHS Arden & GEM CSU \(ardengemcsu.nhs.uk\)](https://ardengemcsu.nhs.uk)
- Please be advised that the NIVS Team **DOES NOT** send communications via text message. If you ever receive a text message claiming to be from NIVS, DO NOT click on any links that are in the text.

Kind regards,

National Immunisation & Vaccination System Support Team

Telephone: **0121 611 0187**

Email: nivs@england.nhs.net

Web: <http://nivs.ardengemcsu.nhs.uk/home>



This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its content, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail.

This email is intended only for use by the named addressee. It may contain confidential and/or privileged information. If you are not the intended recipient, you should contact us/the sender immediately and should not disclose, use or rely on this email. We do not accept any liability arising from a third party taking action, or refraining from taking action, on the basis of information contained in this email. Thank you